Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2322-2329

  Ingels, Alexandre ^a,b   Zhao, Hongjuan ^a   Thong, Alan E ^a   Saar, Matthias ^a,c   Valta, Maija P ^a,d   Nolley, Rosalie ^a   Santos, Jennifer ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BICÊTRE HOSPITAL   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

mTOR inhibitor; renal cell carcinoma; tumorgrafts

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 0128; MYC PROTEIN; PLACEBO; PROTEIN HIF1 ALPHA; PROTEIN MTA1; PROTEIN S6K1; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH;

MTOR INHIBITOR; RENAL CELL CARCINOMA; TUMORGRAFTS;

ADULT; ANIMALS; BENZOXAZOLES; CARCINOMA, RENAL CELL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895921712     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28579     Document Type: Article

References (34)

1. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007; 109: 2257-67.
2. Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007; 177: 346-52.
3. Pal SK, Quinn DI,. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 2013; 39: 709-19.
4. Barthelemy P, Hoch B, Chevreau C, et al. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol 2013; 88: 42-56.
5. Voss MH, Molina AM, Motzer RJ,. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 835-52.
6. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8.
7. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
8. Sparks CA, Guertin DA,. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29: 3733-44.
9. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-13.
10. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
11. Thong AE, Zhao H, Ingels A, et al. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol 2013; pii: S1078-1439(13)00208-1. doi: 10.1016/j.urolonc.2013.05.008.
12. van Rijn RS, Simonetti ER, Hagenbeek A, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003; 102: 2522-31.
13. Zhao H, Nolley R, Chen Z, et al. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 2010; 177: 229-39.
14. Mehrara E, Forssell-Aronsson E, Ahlman H, et al. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007; 67: 3970-5.
15. Nishikawa T, Takaoka M, Ohara T, et al. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. Cancer Biol Ther 2013; 14: 230-6.
16. Makhov PB, Golovine K, Kutikov A, et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012; 11: 1510-17.
17. Patel CG, Patel M, Chakravarty A, et al. Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128. J Clin Oncol 2013; 31 (Suppl):abstr 2567.
18. Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2013; 27: 586-94.
19. Pourdehnad M, Truitt ML, Siddiqi IN, et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA 2013; 110: 11988-93.
20. Gokmen-Polar Y, Liu Y, Toroni RA, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 2012; 136: 673-82.
21. Zhao H, Nolley R, Chen Z, et al. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation 2008; 76: 820-30.
22. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008; 283: 34495-9.
23. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14: 435-46.
24. Mihaly Z, Sztupinszki Z, Surowiak P, et al. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012; 12: 857-72.
25. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
26. Schenone S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011; 18: 2995-3014.
27. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457-68.
28. Du K, Tsichlis PN,. Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24: 7401-9.
29. Efeyan A, Sabatini DM,. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22: 169-76.
30. Chen X, Zhao M, Hao M, et al. Dual inhibition of PI3K and mTOR mitigates feedback-loop pAkt activation to improve tamoxifen response in breast cancer cells. Mol Cancer Res 2013; 11: 1269-78.
31. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40.
32. Brannon AR, Haake SM, Hacker KE, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol 2012; 61: 258-68.
33. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010; 1: 152-63.
34. Staller P,. Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma. Future Oncol 2010; 6: 897-900.